Latest News - AbbVie
Top Corporates Hub
AbbVie
AbbVie Lifts Profit Outlook as Sales Rise
31.10.2025 12:42
AbbVie raised its full-year adjusted earnings outlook, even though profit was pressured by increased expenses during the third quarter.
AbbVie lifts full-year profit outlook amid strong psoriasis drug demand
31.10.2025 12:28
Investing.com - AbbVie has lifted its annual profit guidance, after solid demand for the pharmaceutical group’s Skyrizi psoriasis drug helped third-quarter sales surpass estimates.
AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%
31.10.2025 12:22
AbbVie dipped early Friday, though the drug giant easily beat third-quarter forecasts on the back of its immunology meds.
AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.
31.10.2025 12:20
FEATURE AbbVie stock traded slightly lower Friday as the biopharmaceutical giant reported mixed results across its drug portfolios in the third quarter. Adjusted earnings of $1.86 a share topped the $1.
AbbVie’s (NYSE:ABBV) Q3 Sales Beat Estimates
31.10.2025 12:11
Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q3 CY2025, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.
AbbVie: Q3 Earnings Snapshot
31.10.2025 11:58
ABBV) on Friday reported third-quarter net income of $186 million. On a per-share basis, the North Chicago, Illinois-based company said it had net income of 10 cents. Earnings, adjusted for amortization costs and asset impairment costs, were $1.86 per share.
AbbVie Reports Third-Quarter 2025 Financial Results
31.10.2025 11:49
AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2025.
Stocks Mostly Up Pre-Bell as Traders Parse Apple, Amazon Earnings
31.10.2025 11:22
The benchmark US stock measures were mostly pointing higher before the open Friday as traders digest
Exxon Mobil, Berkshire Earnings and Fed Speakers: Still to Come This Week
31.10.2025 08:34
Investors will tune into earnings from oil majors Chevron and Exxon Mobil on Friday. Here’s what to watch for: Today Earnings: AbbVie, Chevron (read more), Colgate-Palmolive, Exxon Mobil. Federal Reserve speakers: Lorie Logan, Beth Hammack and Raphael Bostic are due to speak at a conference on bank funding in Dallas.
AbbVie posts another win for Rinvoq in Phase III vitiligo trials
30.10.2025 12:32
Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the NSV indication.
ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
30.10.2025 11:01
Today, AbbVie (NYSE: ABBV) has announced that Canada's Drug Agency (CDA-AMC), formerly CADTH, has recommended that ELAHERE® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), be reimbursed with conditions, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.1
AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect
30.10.2025 03:01
Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting results this Friday before market open. Here’s what you need to know.
1 Unpopular Stock That Deserves a Second Chance and 2 Facing Challenges
28.10.2025 04:31
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
United States Breast Reconstruction Market Growth Trends and Forecast Report 2025-2033, Profiles of Mentor Worldwide, AbbVie, Integra, Sientra, Stryker, Establishment Labs, RTI Surgical, TELA Bio
23.10.2025 08:52
The United States Breast Reconstruction Market is projected to grow from US$ 1.02 billion in 2024 to US$ 1.74 billion by 2033, with a CAGR of 6.1% from 2025 to 2033. Key factors driving this growth include rising breast cancer incidences and an increase in breast reconstruction surgeries. The availability of insurance coverage, such as through the Women's Health and Cancer Rights Act, enhances treatment accessibility. Technological advancements like less invasive procedures and 3D-printed implan
Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation
22.10.2025 19:44
We recently published 10 Stock News You Should Not Miss as Tom Lee Reiterates Bullish Market Outlook Amid AI Catalysts. AbbVie Inc. (NYSE:ABBV) is one of the stock news you should not miss. Jim Lebenthal from Cerity Partners said in a recent program on CNBC that he likes AbbVie amid “attractive” valuation and dividend yield. […]
Will Rinvoq’s Superiority Over Humira in SELECT-SWITCH Trial Change AbbVie's (ABBV) Narrative
22.10.2025 19:14
AbbVie recently announced positive topline results from its Phase 3b/4 SELECT-SWITCH trial, showing that Rinvoq (upadacitinib) was significantly more effective than Humira (adalimumab) in achieving low disease activity and remission for adults with moderate to severe rheumatoid arthritis who previously did not respond to a TNF inhibitor. This outcome highlights Rinvoq’s potential to become a more central immunology offering for AbbVie as Humira encounters increased biosimilar...
AbbVie Inc. (ABBV): A Bull Case Theory
22.10.2025 18:31
We came across a bullish thesis on AbbVie Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $233.91 as of October 3rd. ABBV’s trailing and forward P/E were 112.65 and 16.84 respectively according to Yahoo Finance. AbbVie is advancing its oncology […]
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
22.10.2025 14:29
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
22.10.2025 13:00
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.